Anesthesia · Neuromuscular BlockadeRegulatory Approvalcompetitivenear-term

Hikma's Sugammadex Sodium ANDA218728 Receives Abbreviated Approval

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 12:31:15 PM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Hikma's recent Abbreviated Approval for Sugammadex Sodium signifies a new entrant in the neuromuscular blockade market, which could disrupt existing market dynamics. Pharma strategy teams must evaluate competitive responses and potential shifts in market share as Hikma launches its product. Regulatory context from FDA (FDA AP — SUGAMMADEX SODIUM (ORIG)) supports the near-term read. Assessment grounded in 16 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape and consider strategies to respond to Hikma's entry into the market. The strongest clinical anchor is Real-time Neuromuscular Control of Exoskeletons (ClinicalTrials.gov), sub-indication match (nmus rehab). In nmus rehab, 8 regulatory and 4 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311) (Humanexa Signals) — sub-indication match (nmus rehab); entity match (sugammadex sodium). Secondary pressure from Teva's Sugammadex Sodium Receives FDA Approval Status. This approval allows Hikma to enter the market for Sugammadex Sodium, potentially impacting competitors already in the neuromuscular blockade space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUGAMMADEX SODIUM (ORIG) (FDA). Entity match (hikma); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.

Key Opportunities

The entry of Hikma could lead to price competition and affect the revenue streams of current players in the neuromuscular blockade space, necessitating strategic adjustments.
Portfolio teams should assess the competitive landscape and consider strategies to respond to Hikma's entry into the market.

What Would Change This Assessment

This becomes more urgent if Monitor Hikma's launch plans and market uptake of Sugammadex Sodium.
Timeline shift beyond near term would change urgency.
Outcome from Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311) would change the regulatory/clinical read.
Outcome from Teva's Sugammadex Sodium Receives FDA Approval Status would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source

Real-time Neuromuscular Control of Exoskeletons
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Vibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Preoperative Dexamethasone Injection to Improve Local Anesthesia Success in Endodontic Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Teva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
[Ad hoc announcement pursuant to Art.
Rochelow relevance
Sponsor/company relevance (Roche)
FDA document
View source

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
PubMedmedium relevance
Sub-indication match (nmus rehab)
FDA document
View source
Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinica
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Targeting lymphotoxin β receptor: from mechanism to precision therapy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
Sugammadex Sodium
existing competitors

Commercial impact

medium

The entry of Hikma could lead to price competition and affect the revenue streams of current players in the neuromuscular blockade space, necessitating strategic adjustments.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.

What to watch

Monitor Hikma's launch plans and market uptake of Sugammadex Sodium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.